A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review

Neuroscience and Biobehavioral Reviews

Volumn 51, Issue , 2015, Pages 15-30

  Notaras, Michael ^a   Hill, Rachel ^a   Van den Buuse, Maarten ^a,b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

Age of onset; Animal models of schizophrenia; BDNF; Brain morphology; Brain derived neurotrophic factor; Clinical pleiotropy; Cognition; Comorbid symptoms; G196A; Psychosis; Rs6265; Schizophrenia; Therapeutic responsiveness; Val66Met; Val66Met mice

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CLOZAPINE; FLUOXETINE; RISPERIDONE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

AMINO ACID SUBSTITUTION; ANATOMICAL VARIATION; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; BRAIN SIZE; COGNITIVE DEFECT; COMORBIDITY; DINUCLEOTIDE REPEAT; EPISTASIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; ONSET AGE; PHARMACOGENETICS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; SYMPTOMATOLOGY; ANIMAL; BRAIN; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 84922240921     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.12.016     Document Type: Review

References (207)

1. Aas M., Haukvik U.K., Djurovic S., Bergmann O., Athanasiu L., Tesli M.S., Hellvin T., Steen N.E., Agartz I., Lorentzen S., Sundet K., Andreassen O.A., Melle I. BDNF Val66Met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 1(46):181-188.
2. Agartz I., Sedvall G.C., Terenius L., Kulle B., Frigessi A., Hall H., Jonsson E.G. BDNF gene variants and brain morphology in schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B(5):513-523.
3. Alderson R.F., Alterman A.L., Barde Y.-A., Lindsay R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5(3):297-306.
4. Alemany S., Arias B., Aguilera M., Villa H., Moya J., Ibanez M.I., Vossen H., Gasto C., Ortet G., Fananas L. Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences. Br. J. Psychiatry 2011, 199(1):38-42.
5. Alexander N., Osinsky R., Schmitz A., Mueller E., Kuepper Y., Hennig J. The BDNF Val66Met polymorphism affects HPA-axis reactivity to acute stress. Psychoneuroendocrinology 2010, 35(6):949-953.
6. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr. Bull. 1989, 15(1):81.
7. Alonso M., Medina J.H., Pozzo-Miller L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn. Mem. 2004, 11(2):172-178.
8. Anastasia A., Deinhardt K., Chao M.V., Will N.E., Irmady K., Lee F.S., Hempstead B.L., Bracken C. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat. Commun. 2013, 4:2490.
9. Andreasen N.C., Paradiso S., O'Leary D.S. Cognitive dysmetria as an integrative theory of schizophrenia. Schizophr. Bull. 1998, 24(2):203-218.
10. Angelucci F., Brene S., Mathe A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10(4):345-352.
11. Anttila S., Illi A., Kampman O., Mattila K., Lehtimäki T., Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J. Neural Transm. 2005, 112(7):885-890.
12. Arnedo J., Svrakic D.M., del Val C., Romero-Zaliz R., Hernández-Cuervo H., Fanous A.H., Pato M.T., Pato C.N., de Erausquin G.A., Cloninger C.R. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am. J. Psychiatry 2014, (Epub ahead of print).
13. Auld D.S., Mennicken F., Day J.C., Quirion R. Neurotrophins differentially enhance acetylcholine release, acetylcholine content and choline acetyltransferase activity in basal forebrain neurons. J. Neurochem. 2001, 77(1):253-262.
14. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 2012, 64(2):238-258.
15. Baker S.A., Stanford L.E., Brown R.E., Hagg T. Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice. Brain Res. 2005, 1039(1):177-188.
16. Baron M., Gruen R., Rainer J.D., Kane J., Asnis L., Lord S. A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. Am. J. Psychiatry 1985, 142(4):447-455.
17. Bath K.G., Jing D.Q., Dincheva I., Neeb C.C., Pattwell S.S., Chao M.V., Lee F.S., Ninan I. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012, 37(5):1297-1304.
18. Beste C., Schneider D., Epplen J.T., Arning L. The functional BDNF Val66Met polymorphism affects functions of pre-attentive visual sensory memory processes. Neuropharmacology 2011, 60(2):467-471.
19. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 1995, 14(3):187-202.
20. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry 1992, 49(12):921.
21. Brünig I., Penschuck S., Berninger B., Benson J., Fritschy J. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression. Eur. J. Neurosci. 2001, 13(7):1320-1328.
22. Buchanan R.W., Vladar K., Barta P.E., Pearlson G.D. Structural evaluation of the prefrontal cortex in schizophrenia. Am. J. Psychiatry 1998, 155(8):1049-1055.
23. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007, 94(1):1-11.
24. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., Zubieta J.-K. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry 2006, 59(9):812-815.
25. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 2003, 160(12):2209-2215.
26. Celada P., Siuciak J.A., Tran T.M., Altar C.A., Tepper J.M. Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphe serotonergic neurons. Brain Res. 1996, 712(2):293-298.
27. Chang H.-A., Lu R.-B., Shy M.-J., Chang C.-C., Lee M.-S., Huang S.-Y. Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia?. J. Neuropsychiatry Clin. Neurosci. 2009, 21(1):30-37.
28. Chao H.M., Kao H.T., Porton B. BDNF Val66Met variant and age of onset in schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B(4):505-506.
29. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 2003, 4(4):299-309.
30. Chen Z.-Y., Ieraci A., Teng H., Dall H., Meng C.-X., Herrera D.G., Nykjaer A., Hempstead B.L., Lee F.S. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J. Neurosci. 2005, 25(26):6156-6166.
31. Chen Z.-Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.-J., Herrera D.G., Toth M., Yang C., McEwen B.S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314(5796):140-143.
32. Chiang M.-C., Barysheva M., Toga A.W., Medland S.E., Hansell N.K., James M.R., McMahon K.L., De Zubicaray G.I., Martin N.G., Wright M.J. BDNF gene effects on brain circuitry replicated in 455 twins. NeuroImage 2011, 55(2):448-454.
33. Chiaruttini C., Vicario A., Li Z., Baj G., Braiuca P., Wu Y., Lee F., Gardossi L., Baraban J., Tongiorgi E. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(38):16481-16486.
34. Choi H., Lee J., Kim M., Jung S., Lee C., Park S., Kim Y. Association of BDNF Val66Met polymorphism with depressive and cognitive symptoms in patients with schizophrenia. Korean J. Psychopharmacol. 2007, 18(3):143-151.
35. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., Malaspina D. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003, 29(4):671-692.
36. Cotman C.W., Berchtold N.C., Christie L.-A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007, 30(9):464-472.
37. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(7):413-431.
38. Daws L.C., Munn J.L., Valdez M., Frosto-Burke T., Hensler J. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J. Neurochem. 2007, 101(3):641-651.
39. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6(6):463-475.
40. Dean B., Bymaster F., Scarr E. Muscarinic receptors in schizophrenia. Curr. Mol. Med. 2003, 3(5):419-426.
41. Dean B., McLeod M., Keriakous D., McKenzie J., Scarr E. Decreased muscarinic, receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2002, 7(10):1083-1091.
42. Decoster J., van Os J., Kenis G., Henquet C., Peuskens J., De Hert M., van Winkel R. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2011, 156B(3):363-369.
43. DeLisi L.E. The significance of age of onset for schizophrenia. Schizophr. Bull. 1992, 18(2):209-215.
44. Dempster E., Toulopoulou T., McDonald C., Bramon E., Walshe M., Filbey F., Wickham H., Sham P.C., Murray R.M., Collier D.A. Association between BDNF Val66Met genotype and episodic memory. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 134(1):73-75.
45. Dincheva I., Glatt C.E., Lee F.S. Impact of the BDNF Val66Met polymorphism on cognition implications for behavioral genetics. Neuroscientist 2012, 18(5):439-451.
46. Dougherty L.R., Klein D.N., Congdon E., Canli T., Hayden E.P. Interaction between 5-HTTLPR and BDNF Val66Met polymorphisms on HPA axis reactivity in preschoolers. Biol. Psychol. 2010, 83(2):93-100.
47. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59(12):1116-1127.
48. Egan M., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
49. Egan M.F., Weinberger D.R., Lu B. Schizophrenia, III: brain-derived neurotropic factor, genetic risk. Am. J. Psychiatry 2003, 160(7):1242.
50. Falkai P., Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatry Clin. Neurosci. 1986, 236(3):154-161.
51. Fanous A.H., Neale M.C., Straub R.E., Webb B.T., O'Neill A.F., Walsh D., Kendler K.S. Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 125B(1):69-78.
52. Fayard B., Loeffler S., Weis J., Vögelin E., Krüttgen A. The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. J. Neurosci. Res. 2005, 80(1):18-28.
53. Feher A., Juhasz A., Rimanoczy A., Szekeres G., Janka Z. P.1.12 Brain-derived neurotrophic factor and dopamine D3 receptor polymorphisms in schizophrenia and therapeutic response. Eur. Neuropsychopharmacol. 2009, 19:S12-S13.
54. Fenton W.S., McGlashan T.H., Victor B.J., Blyler C.R. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am. J. Psychiatry 1997, 154(2):199-204.
55. Friedman J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berlin) 2004, 174(1):45-53.
56. Garcia K.L., Yu G., Nicolini C., Michalski B., Garzon D.J., Chiu V.S., Tongiorgi E., Szatmari P., Fahnestock M. Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism. J. Neuropathol. Exp. Neurol. 2012, 71(4):289.
57. Gatt J., Nemeroff C., Dobson-Stone C., Paul R., Bryant R., Schofield P., Gordon E., Kemp A., Williams L. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol. Psychiatry 2009, 14(7):681-695.
58. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull. 1987, 13(4):643-668.
59. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57(1):65-73.
60. Glerup S., Olsen D., Vaegter C.B., Gustafsen C., Sjoegaard S.S., Hermey G., Kjolby M., Molgaard S., Ulrichsen M., Boggild S. SorCS2 regulates dopaminergic wiring and is processed into an apoptotic two-chain receptor in peripheral glia. Neuron 2014, 82(5):1074-1087.
61. Goggi J., Pullar I.A., Carney S.L., Bradford H.F. Signalling pathways involved in the short-term potentiation of dopamine release by BDNF. Brain Res. 2003, 968(1):156-161.
62. Golimbet V.E., Korovaitseva G.I., Abramova L.I., Kasparov S.V., Uvarova L.G. Association of the Val66Met polymorphism of the brain-derived neurotrophic factor gene with schizophrenia in Russians. Mol. Biol. 2008, 42(4):531-535.
63. Gourion D., Goldberger C., Leroy S., Bourdel M.-C., Olié J.-P., Krebs M.-O. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. Neuroreport 2005, 16(12):1407-1410.
64. Gratacòs M., González J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry 2007, 61(7):911-922.
65. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411(6833):86-89.
66. Guillin O., Griffon N., Diaz J., Foll B.L., Bezard E., Gross C., Lammers C., Stark H., Carroll P., Schwartz J.-C. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int. Rev. Neurobiol. 2004, 59:425-444.
67. Guilloux J.-P., Douillard-Guilloux G., Kota R., Wang X., Gardier A., Martinowich K., Tseng G.C., Lewis D.A., Sibille E. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol. Psychiatry 2011, 17(11):1130-1142.
68. Hajek T., Kopecek M., Höschl C. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis. World J. Biol. Psychiatry 2012, 13(3):178-187.
69. Han D.H., Park D.B., Choi T.Y., Joo S.Y., Lee M.K., Park B.R.G., Nishimura R., Chu C.-C., Renshaw P.F. Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms. Neuroreport 2008, 19(11):1155-1158.
70. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003, 23(17):6690-6694.
71. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berlin) 2004, 174(1):151-162.
72. Harrison P.J., Eastwood S.L. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 2001, 11(5):508-519.
73. Hashim H.M., Fawzy N., Fawzi M.M., Karam R.A. Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients. J. Psychiatr. Res. 2012, 46(6):762-766.
74. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001, 11(5):520-528.
75. Hill R., Wu Y., Kwek P., van den Buuse M. Modulatory effects of sex steroid hormones on brain-derived neurotrophic factor-tyrosine kinase B expression during adolescent development in C57Bl/6 mice. J. Neuroendocrinol. 2012, 24(5):774-788.
76. Ho B.C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am. J. Psychiatry 2007, 164(12):1890-1899.
77. Ho B.C., Milev P., O'Leary D.S., Librant A., Andreasen N.C., Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 2006, 63(7):731-740.
78. Hoffman D.C., Donovan H., Cassella J.V. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berlin) 1993, 111(3):339-344.
79. Hong C.-J., Liou Y.-J., Tsai S.-J. Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res. Bull. 2011, 86(5):287-297.
80. Hong C.-J., Yu Y.W.Y., Lin C.-H., Tsai S.-J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 2003, 349(3):206-208.
81. Hong K.W., Lim J.E., Go M.J., Shin Y.S., Ahn Y., Han B.G., Oh B. Recapitulation of the association of the Val66Met polymorphism of BDNF gene with BMI in Koreans. Obesity 2012, 20(9):1871-1875.
82. Huang T.L., Lee C.T. Associations between brain-derived neurotrophic factor G196A gene polymorphism and clinical phenotypes in schizophrenia patients. Chang Gung Med. J. 2007, 30(5):408-413.
83. Iga J.-I., Ueno S.-I., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., Nakataki M., Song H., Hokoishi K., Tanabe H., Sano A., Ohmori T. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B(8):1003-1006.
84. Jeanneteau F.D., Lambert W.M., Ismaili N., Bath K.G., Lee F.S., Garabedian M.J., Chao M.V. BDNF and glucocorticoids regulate corticotrophin-releasing hormone (CRH) homeostasis in the hypothalamus. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(4):1305-1310.
85. Jönsson E.G., Edman-Ahlbom B., Sillen A., Gunnar A., Kulle B., Frigessi A., Vares M., Ekholm B., Wode-Helgodt B., Schumacher J., Cichon S., Agartz I., Sedvall G.C., Hall H., Terenius L. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(5):924-933.
86. Jovanovic J.N., Czernik A.J., Fienberg A.A., Greengard P., Sihra T.S. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat. Neurosci. 2000, 3(4):323-329.
87. Joyce J.N., Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 2005, 10(13):917-925.
88. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr. Genet. 2007, 17(3):165-170.
89. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 1996, 153(4):466-476.
90. Karnik M.S., Wang L., Barch D.M., Morris J.C., Csernansky J.G. BDNF polymorphism rs6265 and hippocampal structure and memory performance in healthy control subjects. Psychiatry Res. 2010, 178(2):425-429.
91. Kaufman J., Yang B.Z., Douglas-Palumberi H., Grasso D., Lipschitz D., Houshyar S., Krystal J.H., Gelernter J. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol. Psychiatry 2006, 59(8):673-680.
92. Kawashima K., Ikeda M., Kishi T., Kitajima T., Yamanouchi Y., Kinoshita Y., Okochi T., Aleksic B., Tomita M., Okada T., Kunugi H., Inada T., Ozaki N., Iwata N. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr. Res. 2009, 112(1-3):72-79.
93. Kennedy K.M., Rodrigue K.M., Land S.J., Raz N. BDNF Val66Met polymorphism influences age differences in microstructure of the corpus callosum. Front. Hum. Neurosci. 2009, 3:19.
94. Klug M., Hill R.A., Choy K.H.C., Kyrios M., Hannan A.J., van den Buuse M. Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol. Dis. 2012, 46(3):722-731.
95. Knipper M., Penha Berzaghi M., Blöchl A., Breer H., Thoenen H., Lindholm D. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur. J. Neurosci. 1994, 6(4):668-671.
96. Knüsel B., Winslow J.W., Rosenthal A., Burton L.E., Seid D.P., Nikolics K., Hefti F. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(3):961-965.
97. Kolluri N., Sun Z., Sampson A.R., Lewis D.A. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2005, 162(6):1200-1202.
98. Koolschijn P.C., van Haren N.E., Bakker S.C., Hoogendoorn M.L., Hulshoff Pol H.E., Kahn R.S. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 2010, 20(9):1010-1017.
99. Korte M., Carroll P., Wolf E., Brem G., Thoenen H., Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(19):8856-8860.
100. Kovalchuk Y., Hanse E., Kafitz K.W., Konnerth A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science 2002, 295(5560):1729-1734.
101. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., Sokoloff P. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry 2000, 5(5):558-562.
102. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13(1):9-19.
103. Lee H.Y., Kim D.J., Kim Y.K. An association study of the brain-derived neurotrophic factor Val66Met gene polymorphism and schizophrenia. Korean J. Biol. Psychiatry 2006, 13(4):267-272.
104. Lee K.-H., Williams L.M., Breakspear M., Gordon E. Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain Res. Rev. 2003, 41(1):57-78.
105. Lencz T., Lipsky R.H., DeRosse P., Burdick K.E., Kane J.M., Malhotra A.K. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br. J. Psychiatry 2009, 194(4):313-318.
106. Lewis D.A., González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2007, 33(1):141-165.
107. Li Y.-X., Zhang Y., Lester H.A., Schuman E.M., Davidson N. Enhancement of neurotransmitter release induced by brain-derived neurotrophic factor in cultured hippocampal neurons. J. Neurosci. 1998, 18(24):10231-10240.
108. Light G.A., Hsu J.L., Hsieh M.H., Meyer-Gomes K., Sprock J., Swerdlow N.R., Braff D.L. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol. Psychiatry 2006, 60(11):1231-1240.
109. Lin Z., Su Y., Zhang C., Xing M., Ding W., Liao L., Guan Y., Li Z., Cui D. The Interaction of BDNF and NTRK2 gene increases the susceptibility of paranoid schizophrenia. PLOS ONE 2013, 8(9):e74264.
110. Liu R.-J., Lee F.S., Li X.-Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71(11):996-1005.
111. Loh H.C., Tang P.Y., Tee S.F., Chow T.J., Cheah Y.C., Singh S.S. BDNF and DARPP-32 genes are not risk factors for schizophrenia in the Malay population. Genet. Mol. Res. 2012, 11(1):725-730.
112. Lu W., Zhang C., Yi Z., Li Z., Wu Z., Fang Y. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J. Mol. Neurosci. 2012, 47(3):505-510.
113. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., Wihler C., Koliatsos V.E., Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(26):15239-15244.
114. Madhav T., Pei Q., Zetterström T. Serotonergic cells of the rat raphe nuclei express mRNA of tyrosine kinase B (trkB), the high-affinity receptor for brain derived neurotrophic factor (BDNF). Mol. Brain Res. 2001, 93(1):56-63.
115. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17(3):141-150.
116. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J. Neurosci. 1995, 15(12):7929-7939.
117. Mandelman S.D., Grigorenko E.L. BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav 2012, 11(2):127-136.
118. Marenco S., Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 2000, 12(3):501-527.
119. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2007, 33(1):73-83.
120. McGuffin P., Owen M.J., Farmer A.E. Genetic basis of schizophrenia. Lancet 1995, 346(8976):678-682.
121. Minzenberg M.J., Firl A.J., Yoon J.H., Gomes G.C., Reinking C., Carter C.S. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. Neuropsychopharmacology 2010, 35(13):2590-2599.
122. Molendijk M.L., Bus B.A., Spinhoven P., Kaimatzoglou A., Voshaar R.C.O., Penninx B.W., van IJzendoorn M.H., Elzinga B.M. A systematic review and meta-analysis on the association between BDNF Val66Met and hippocampal volume - a genuine effect or a winners curse?. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2012, 159(6):731-740.
123. Montag C., Basten U., Stelzel C., Fiebach C.J., Reuter M. The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. Psychiatry Res. 2010, 179(1):86-90.
124. Montag C., Weber B., Fliessbach K., Elger C., Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol. Med. 2009, 39(11):1831-1839.
125. Morice R. Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br. J. Psychiatry 1990, 157(1):50-54.
126. Mowla S.J., Farhadi H.F., Pareek S., Atwal J.K., Morris S.J., Seidah N.G., Murphy R.A. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J. Biol. Chem. 2001, 276(16):12660-12666.
127. Naoe Y., Shinkai T., Hori H., Fukunaka Y., Utsunomiya K., Sakata S., Matsumoto C., Shimizu K., Hwang R., Ohmori O. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case-control study and meta-analysis. Neurosci. Lett. 2007, 415(2):108-112.
128. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39(11):1763.
129. Nemoto K., Ohnishi T., Mori T., Moriguchi Y., Hashimoto R., Asada T., Kunugi H. The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology. Neurosci. Lett. 2006, 397(1):25-29.
130. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., Sinclair M., Crombie C., Walker N., St Clair D.M. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 2005, 10(2):208-212.
131. Ninan I., Bath K.G., Dagar K., Perez-Castro R., Plummer M.R., Lee F.S., Chao M.V. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J. Neurosci. 2010, 30(26):8866-8870.
132. Nolan K.A., Bilder R.M., Lachman H.M., Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am. J. Psychiatry 2004, 161(2):359-361.
133. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Kinouchi S., Shibuya-Tayoshi S., Tayoshi S., Aki H., Sumitani S., Itakura M., Ohmori T. Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia. J. Neural Transm. 2007, 114(2):255-259.
134. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Ohta K., Kinouchi S., Shibuya-Tayoshi S., Tayoshi S., Aono M., Kameoka N., Sumitani S., Tomotake M., Kaneda Y., Taniguchi T., Ishimoto Y., Ohmori T. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci. Lett. 2006, 401(1-2):1-5.
135. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.-H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306(5695):487-491.
136. Patterson S.L., Grover L.M., Schwartzkroin P.A., Bothwell M. Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron 1992, 9(6):1081-1088.
137. Pattwell S.S., Bath K.G., Perez-Castro R., Lee F.S., Chao M.V., Ninan I. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J. Neurosci. 2012, 32(7):2410-2421.
138. Petrella J.R., Mattay V.S., Doraiswamy P.M. Imaging genetics of brain longevity and mental wellness: the next frontier?. Radiology 2008, 246(1):20-32.
139. Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fan J.B., Schaffner S., Waggoner S.G., Tahl A.R., Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 2009, 15(8):810-815.
140. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor Val66Met polymorphism and variation in human cortical morphology. J. Neurosci. 2004, 24(45):10099-10102.
141. Pregelj P., Nedic G., Paska A.V., Zupanc T., Nikolac M., Balažic J., Tomori M., Komel R., Seler D.M., Pivac N. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J. Affect. Disord. 2011, 128(3):287-290.
142. Pruunsild P., Kazantseva A., Aid T., Palm K., Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007, 90(3):397-406.
143. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., Zhu S., He L. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem. Biophys. Res. Commun. 2007, 353(3):738-743.
144. Rage F., Givalois L., Marmigere F., Tapia-Arancibia L., Arancibia S. Immobilization stress rapidly modulates BDNF mRNA expression in the hypothalamus of adult male rats. Neuroscience 2002, 112(2):309-318.
145. Ribasés M., Gratacòs M., Fernández-Aranda F., Bellodi L., Boni C., Anderluh M., Cavallini M.C., Cellini E., Di Bella D., Erzegovesi S. Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum. Mol. Genet. 2004, 13(12):1205-1212.
146. Richter-Schmidinger T., Alexopoulos P., Horn M., Maus S., Reichel M., Rhein C., Lewczuk P., Sidiropoulos C., Kneib T., Perneczky R. Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J. Neural Transm. 2011, 118(2):249-257.
147. Rosa A., Cuesta M.J., Fatjó-Vilas M., Peralta V., Zarzuela A., Fañanás L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141(2):135-138.
148. Rybakowski J.K., Borkowska A., Skibinska M., Szczepankiewicz A., Kapelski P., Leszczynska-Rodziewicz A., Czerski P.M., Hauser J. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin. Neurosci. 2006, 60(1):70-76.
149. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLOS Med. 2005, 2(5):e141.
150. Scarr E., Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. J. Neurochem. 2008, 107(5):1188-1195.
151. Scarr E., Sundram S., Keriakous D., Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry 2007, 61(10):1161-1170.
152. Schaaf M.J., de Jong J., de Kloet E.R., Vreugdenhil E. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res. 1998, 813(1):112-120.
153. Schenkel L.C., Segal J., Becker J.A., Manfro G.G., Bianchin M.M., Leistner-Segal S. The BDNF Val66Met polymorphism is an independent risk factor for high lethality in suicide attempts of depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(6):940-944.
154. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., Schulze T.G., Deschner M., Schmäl C., Höfels S., Zobel A., Illig T., Propping P., Holsboer F., Rietschel M., Nöthen M.M., Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol. Psychiatry 2005, 58(4):307-314.
155. Seidah N.G., Benjannet S., Pareek S., Chrétien M., Murphy R.A. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett. 1996, 379(3):247-250.
156. Shalev I., Lerer E., Israel S., Uzefovsky F., Gritsenko I., Mankuta D., Ebstein R.P., Kaitz M. BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. Psychoneuroendocrinology 2009, 34(3):382-388.
157. Shetty A.K., Turner D.A. In vitro survival and differentiation of neurons derived from epidermal growth factor-responsive postnatal hippocampal stem cells: inducing effects of brain-derived neurotrophic factor. J. Neurobiol. 1998, 35(4):395-425.
158. Simons C., Wichers M., Derom C., Thiery E., Myin-Germeys I., Krabbendam L., van Os J. Subtle gene-environment interactions driving paranoia in daily life. Genes Brain Behav. 2009, 8(1):5-12.
159. Skibinska M., Kapelski P., Slopien A., Leszczynska-Rodziewicz A., Godlewska B., Wilkosc M., Tomaszewska M., Dmitrzak-Weglarz M., Czerski P. Association study of four polymorphisms of brain-derived neurotrophic factor (BDNF) gene with schizophrenia. Eur. Neuropsychopharmacol. 2008, 18(Suppl. 4):S215. (p.211.a.022).
160. Smith G.N., Thornton A.E., Lang D.J., Macewan G.W., Ehmann T.S., Kopala L.C., Tee K., Shiau G., Voineskos A.N., Kennedy J.L., Honer W.G. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophr. Res. 2012, 134(2-3):253-259.
161. Soliman F., Glatt C.E., Bath K.G., Levita L., Jones R.M., Pattwell S.S., Jing D., Tottenham N., Amso D., Somerville L.H. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 2010, 327(5967):863-866.
162. Spalletta G., Morris D.W., Angelucci F., Rubino I.A., Spoletini I., Bria P., Martinotti G., Siracusano A., Bonaviri G., Bernardini S., Caltagirone C., Bossu P., Donohoe G., Gill M., Corvin A.P. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur. Psychiatry 2010, 25(6):311-313.
163. Squassina A., Piccardi P., Del Zompo M., Rossi A., Vita A., Pini S., Mucci A., Galderisi S. NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample. Psychiatry Res. 2010, 176(1):82-84.
164. Sublette M.E., Baca-Garcia E., Parsey R.V., Oquendo M.A., Rodrigues S.M., Galfalvy H., Huang Y.Y., Arango V., Mann J.J. Effect of BDNF Val66met polymorphism on age-related amygdala volume changes in healthy subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(7):1652-1655.
165. Suchanek R., Owczarek A., Paul-Samojedny M., Kowalczyk M., Kucia K., Kowalski J. BDNF Val66Met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 2013, 25(1):88-94.
166. Sullivan P.F. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010, 68(2):182-186.
167. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60(12):1187-1192.
168. Sun M.-M., Yang L.-M., Wang Y., Feng X., Cui K.-Y., Liu L.-F., Chen Z.-Y. BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population. Psychiatr. Genet. 2013, 23(3):124-129.
169. Szeszko P., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., Ashtari M., Napolitano B., Bilder R., Kane J. Brain-derived neurotrophic factor Val66Met polymorphism and volume of the hippocampal formation. Mol. Psychiatry 2005, 10(7):631-636.
170. Takahashi T., Suzuki M., Tsunoda M., Kawamura Y., Takahashi N., Tsuneki H., Kawasaki Y., Zhou S.Y., Kobayashi S., Sasaoka T., Seto H., Kurachi M., Ozaki N. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci. Lett. 2008, 435(1):34-39.
171. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Wu G.Y., Zhang X.Y. Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophr. Res. 2005, 77(2-3):355-356.
172. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110(1):1-23.
173. Tandon R., Taylor S.F., DeQuardo J.R., Eiser A., Jibson M.D., Goldman M. The cholinergic system in schizophrenia reconsidered: anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology 1999, 21:S189-S202.
174. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.-Y., Lee F.S., Kraemer R.T., Nykjaer A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci. 2005, 25(22):5455-5463.
175. Thompson J.L., Pogue-Geile M.F., Grace A.A. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr. Bull. 2004, 30(4):875-900.
176. Tienari P., Wynne L.C., Moring J., Lahti I. The Finnish adoptive family study of schizophrenia: implications for family research. Br. J. Psychiatry 1994, 164:20-26.
177. Tochigi M., Otowa T., Suga M., Rogers M., Minato T., Yamasue H., Kasai K., Kato N., Sasaki T. No evidence for an association between the BDNF Val66Met polymorphism and schizophrenia or personality traits. Schizophr. Res. 2006, 87(1-3):45-47.
178. Tolwani R., Buckmaster P., Varma S., Cosgaya J., Wu Y., Suri C., Shooter E. BDNF overexpression increases dendrite complexity in hippocampal dentate gyrus. Neuroscience 2002, 114(3):795-805.
179. Tong L., Balazs R., Soiampornkul R., Thangnipon W., Cotman C.W. Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol. Aging 2008, 29(9):1380-1393.
180. Tost H., Alam T., Geramita M., Rebsch C., Kolachana B., Dickinson D., Verchinski B.A., Lemaitre H., Barnett A.S., Trampush J.W., Weinberger D.R., Marenco S. Effects of the BDNF Val66Met polymorphism on white matter microstructure in healthy adults. Neuropsychopharmacology 2013, 38(3):525-532.
181. Tsuang M.T., Stone W.S., Faraone S.V. Genes, environment and schizophrenia. Br. J. Psychiatry 2001, 178(40):s18-s24.
182. Tyler W.J., Pozzo-Miller L.D. BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. J. Neurosci. 2001, 21(12):4249-4258.
183. van Amelsvoort T., Schmitz N., Zinkstok J., de Haan L., Baas F., Linszen D. Effect of BDNF Val66Met polymorphism on brain anatomy in first episode schizophrenia. Schizophr. Res. 2008, 102(1):83.
184. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 2010, 36(2):246-270.
185. Ventimiglia R., Mather P.E., Jones B.E., Lindsay R.M. The NeurotroDhins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci. 1995, 7(2):213-222.
186. Verhagen M., Van Der Meij A., Van Deurzen P., Janzing J., Arias-Vasquez A., Buitelaar J., Franke B. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry 2010, 15(3):260-271.
187. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9(17):3897-3902.
188. Vutskits L., Djebbara-Hannas Z., Zhang H., Paccaud J.P., Durbec P., Rougon G., Muller D., Kiss J.Z. PSA-NCAM modulates BDNF-dependent survival and differentiation of cortical neurons. Eur. J. Neurosci. 2001, 13(7):1391-1402.
189. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104(4):667-685.
190. Ward N.L., Hagg T. BDNF is needed for postnatal maturation of basal forebrain and neostriatum cholinergic neurons in vivo. Exp. Neurol. 2000, 162(2):297-310.
191. Weinberger D.R., Gallhofer B. Cognitive function in schizophrenia. J. Clin. Psychopharmacol. 1997, 12:s29-s36.
192. Wu Y.C., Hill R.A., Klug M., van den Buuse M. Sex-specific and region-specific changes in BDNF-TrkB signalling in the hippocampus of 5-HT1A receptor and BDNF single and double mutant mice. Brain Res. 2012, 1452:10-17.
193. Xiu M.H., Zhang X.Y. Serum BDNF levels are determined by functional polymorphism Val66Met and associated with cognitive impairment in chronic schizophrenia. Schizophr. Res. 2010, 117(2):386.
194. Xu M., Li S., Xing Q., Gao R., Feng G., Lin Z., St Clair D., He L. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur. J. Hum. Genet. 2010, 18(6):707-712.
195. Xu M.Q., St Clair D., Ott J., Feng G.Y., He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr. Res. 2007, 91(1-3):6-13.
196. Yang X., Liu P., Sun J., Wang G., Zeng F., Yuan K., Liu J., Dong M., von Deneen K.M., Qin W., Tian J. Impact of brain-derived neurotrophic factor Val66Met polymorphism on cortical thickness and voxel-based morphometry in healthy Chinese young adults. PLoS ONE 2012, 7(6):e37777.
197. Yi Z., Zhang C., Wu Z., Hong W., Li Z., Fang Y., Yu S. Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res. 2011, 1417:146-150.
198. Yu H., Wang D.D., Wang Y., Liu T., Lee F.S., Chen Z.Y. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 2012, 32(12):4092-4101.
199. Zai G.C., Zai C.C., Chowdhury N.I., Tiwari A.K., Souza R.P., Lieberman J.A., Meltzer H.Y., Potkin S.G., Muller D.J., Kennedy J.L. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39(1):96-101.
200. Zakharyan R., Boyajyan A., Arakelyan A., Gevorgyan A., Mrazek F., Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population. Hum. Immunol. 2011, 72(9):746-748.
201. Zhai J., Yu Q., Chen M., Gao Y., Zhang Q., Li J., Wang K., Ji F., Su Z., Li W. Association of the brain-derived neurotrophic factor gene G196A rs6265 polymorphisms and the cognitive function and clinical symptoms of schizophrenia. Int. J. Clin. Exp. Pathol. 2013, 6(8):1617-1623.
202. Zhang L., Benedek D., Fullerton C., Forsten R., Naifeh J., Li X., Hu X., Li H., Jia M., Xing G. PTSD risk is associated with BDNF Val66Met and BDNF overexpression. Mol. Psychiatry 2013, 19:8-10.
203. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., Zhang H.P., Zuo L., Zhang Z., Zhang X., Kosten T.A., Kosten T.R. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum. Genet. 2012, 131(7):1187-1195.
204. Zhang X.Y., Zhang W.F., Zhou D.F., Chen da C., Xiu M.H., Wu H.R., Haile C.N., Kosten T.A., Kosten T.R. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol. Psychiatry 2012, 72(8):700-706.
205. Zheng K., An J.J., Yang F., Xu W., Xu Z.-Q.D., Wu J., Hökfelt T.G., Fisahn A., Xu B., Lu B. TrkB signaling in parvalbumin-positive interneurons is critical for gamma-band network synchronization in hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(41):17201-17206.
206. Zhou D.H., Yan Q.Z., Yan X.M., Li C.B., Fang H., Zheng Y.L., Zhang C.X., Yao H.J., Chen da C., Xiu M.H., Kosten T.R., Zhang X.Y. The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(6):930-933.
207. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr. Genet. 2007, 17(2):69-75.